18:37 , Apr 4, 2019 |  BC Extra  |  Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

FDA Commissioner Scott Gottlieb will return to the American Enterprise Institute as a resident fellow after he leaves the agency. His last day at FDA is Friday. Gottlieb expects to work part-time at AEI, where...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
22:03 , Dec 30, 2016 |  BC Week In Review  |  Company News

Transgene, ElsaLys deal

Transgene granted ElsaLys exclusive, worldwide rights, except in greater China, to develop and commercialize preclinical immuno-oncology candidate ELB041 (formerly TG3003), a human mAb against CD115 . ElsaLys hopes to begin clinical development before year end...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

Institut National de la Sante et de la Recherche Medicale, ElsaLys Biotech deal

The institute granted ElsaLys exclusive, worldwide rights to CD160 for use in ophthalmology. The company and institute did not respond to inquiries. Last year, MABLife S.A.S (Evry, France) granted ElsaLys exclusive, worldwide rights to develop...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Financial News

ElsaLys Biotech completes venture financing

ElsaLys Biotech , Lyon, France   Business: Antibodies, Cancer, Inflammation   Date completed: 2015-11-03   Type: Venture financing   Raised: EUR2.7 million ($3 million)   Investors: Sofimac; Institut Merieux ; Credit Agricole   Note: ElsaLys...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Company News

MABLife, ElsaLys Biotech deal

MABLife granted ElsaLys exclusive worldwide rights to develop and commercialize MAT-302 . ElsaLys said it will develop two versions of the antibody, one to treat macular degeneration and one to treat B cell chronic lymphocytic...
07:00 , May 20, 2013 |  BC Week In Review  |  Financial News

ElsaLys Biotech completes venture financing

ElsaLys Biotech , Lyon, France   Business: Antibodies, Cancer, Inflammation   Date completed: 5/17/13   Type: Venture financing   Raised: €2.1 million ($2.7 million)   Investors: Transgene S.A. ; Sofimac  ...